|
Jun 16
|
ENDRA’s Ongoing Multisite Pilot Study Reveals Important Enhancements to Boost TAEUS Liver Accuracy and Repeatability Against MRI Gold Standard
|
|
Aug 28
|
ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements
|
|
Aug 7
|
ENDRA Life Sciences to Report Second Quarter 2024 Financial Results on August 14
|
|
May 7
|
ENDRA Life Sciences to Report First Quarter 2024 Financial Results on May 14, 2024
|
|
May 2
|
ENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International Patents
|
|
Nov 29
|
ENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System Technology
|
|
Nov 27
|
ENDRA Life Sciences to Participate in The Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference
|
|
Nov 14
|
ENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
|
|
Nov 8
|
ENDRA Life Sciences Achieves Intellectual Property Milestone with Issuance of Three New Patents
|
|
Nov 7
|
ENDRA Life Sciences to Report Third Quarter 2023 Financial Results on November 14, 2023
|
|
Nov 6
|
ENDRA to Host Multidisciplinary Clinical Discussion on Managing Liver Disease During AASLD’s The Liver Meeting® 2023
|
|
Aug 23
|
ENDRA Life Sciences Expands Intellectual Property with Issuance of U.S. and European Patents
|
|
Aug 20
|
ENDRA Life Sciences Inc. (NASDAQ:NDRA) Q2 2023 Earnings Call Transcript
|